HeartBeam Earnings Call: Funding Extends Runway, Trials Advance

Heartbeam, Inc. ((BEAT)) has held its Q1 earnings call. Read on for the main highlights of the call.

HeartBeam’s latest earnings call struck a cautiously upbeat tone, as management highlighted fresh funding, clinical momentum, and early commercial traction that help offset continuing losses and minimal near-term revenue. Executives framed 2026 as a pivotal de‑risking year, with reduced cash burn and a longer runway giving the company room to execute on key milestones.

Balance Sheet Bolstered by $11.5 Million Offering

HeartBeam closed an underwritten public offering on April 16, raising $11.5 million in gross proceeds and lifting pro forma cash to about $12.4 million. Management said this capital injection extends the company’s operating runway into 2027, easing pressure after ending March with just over $2 million on hand.

Improving Cash Burn but Losses Still Significant

The company reported a Q1 2026 net loss of $4.7 million and used $3.6 million in operating cash, but that represented a 19% year-over-year reduction in burn. Management reiterated that HeartBeam remains in investment mode and expects multi-quarter cash outflows to continue even as spending is managed more tightly.

Anchor Commercial Partnerships in Key U.S. Markets

On the commercial front, HeartBeam signed its first partnership in Q1 with ClearCardio, covering New York City, Dallas, and South Florida, and later added Atelier Health in the Beverly Hills area. These relationships establish a flagship presence in all four of the company’s initial target geographies and create an early beachhead in the Direct Pay concierge segment.

Prototype 12-Lead Patch and European Pilot Study

The company completed a working prototype of its on-demand 12‑lead ECG patch in the first quarter and has already initiated a European pilot ischemia study. That pilot will enroll roughly 50 high-risk patients undergoing exercise stress testing to compare HeartBeam’s synthesized 12‑lead ECGs with standard clinical 12‑lead ECGs.

Momentum in Heart Attack Detection Clinical Program

HeartBeam enrolled the first patient in its ALIGN‑ACS pilot, which is expected to include 100 to 120 patients and is currently ahead of schedule. Management expects enrollment to wrap by the end of the third quarter of 2026, while a largely government-funded HEADSTART‑ACS study in Indonesia is planned at around 500 patients.

Regulatory Beachhead with Two FDA Clearances

While the critical myocardial infarction indication remains in development, the company has already secured two FDA clearances for arrhythmia assessment using its system. These limited indications allow for a constrained commercial launch today and provide a regulatory foundation to pursue broader label expansions later.

AI Partnership with Mount Sinai for Next-Gen Algorithms

HeartBeam finalized a strategic collaboration with Mount Sinai focused on building advanced AI algorithms for heart attack detection, wellness, and personalized cardiac assessment. The effort will leverage HeartBeam’s 3D ECG signal collection and the expected ~1,000‑patient dataset from ALIGN‑ACS, HEADSTART‑ACS, and pivotal work.

Lean, Targeted Launch and Subscription Pricing Model

The company is rolling out its product with a capital-efficient model, initially assigning just a sales director and implementation specialist per geography. Pricing remains in the $750 to $1,000 annual subscription range, and management expects many early accounts to pay the first year’s fees upfront, front-loading cash receipts.

Limited Near-Term Revenue and Adoption Risk

Executives were clear that the first half of 2026 is not about revenue, with only modest sales expected in the second quarter and more meaningful ramping envisioned in late 2026 and 2027. With few current customers and no direct-to-consumer strategy, revenue visibility depends on how quickly a small set of anchor practices adopt the platform.

Dependence on Partnerships for Patch Commercialization

Management views the 12‑lead patch as a gateway into a roughly $2 billion ambulatory monitoring market but stressed that commercialization will rely on industry partnerships. Discussions with potential partners are ongoing, yet no definitive distribution or commercialization deals have been announced so far.

Forward-Looking Guidance and Runway into 2027

Looking ahead, HeartBeam expects full-year 2026 cash outflows to come in under $16 million, down from prior guidance of $17 million to $19 million, with Q1’s $3.6 million implying around $12 million of remaining outflows before customer receipts. Management believes current cash and front-loaded subscription payments should fund operations into 2027, while clinical programs advance toward roughly 1,000 patients to support AI and MI algorithm development and the company targets a Direct Pay base with a breakeven near 30,000 patients.

HeartBeam’s earnings call painted the picture of a company still early in its commercial journey but steadily de-risking its story through financing, clinical progress, and strategic partnerships. For investors, the thesis now hinges on execution: converting flagship accounts, securing patch distribution partners, and turning promising clinical and AI work into durable, scalable revenue growth over the next several years.